Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized … LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ... Diabetes Care 41 (5), 1009-1016, 2018 | 203 | 2018 |
Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease–a population‐based study C Jakobsen, J Bartek Jr, V Wewer, I Vind, P Munkholm, R Grøn, ... Alimentary pharmacology & therapeutics 34 (10), 1217-1224, 2011 | 181 | 2011 |
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b … VR Aroda, G González-Galvez, R Grøn, N Halladin, M Haluzík, ... The lancet Diabetes & endocrinology 7 (8), 596-605, 2019 | 68 | 2019 |
Maternal depression, antidepressant use in pregnancy and Apgar scores in infants R Gr, Ø Lidegaard, LH Pedersen, PK Andersen, LV Kessing The British Journal of Psychiatry 202 (5), 347-351, 2013 | 52 | 2013 |
Active smoking and risk of breast cancer in a Danish nurse cohort study ZJ Andersen, JT Jørgensen, R Grøn, EV Brauner, E Lynge BMC cancer 17, 1-11, 2017 | 43 | 2017 |
The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age HM Jensen, R Grøn, Ø Lidegaard, LH Pedersen, PK Andersen, ... Psychopharmacology 228, 199-205, 2013 | 36 | 2013 |
Risk factors for venous thromboembolism during pregnancy TB Jensen, TA Gerds, R Grøn, DM Bretler, MD Schmiegelow, ... Pharmacoepidemiology and drug safety 22 (12), 1283-1291, 2013 | 31 | 2013 |
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: a DEVOTE subanalysis (DEVOTE 10) K Brown‐Frandsen, SS Emerson, DK McGuire, TR Pieber, NR Poulter, ... Diabetes, Obesity and Metabolism 21 (6), 1437-1444, 2019 | 15 | 2019 |
Nonparametric estimation in an “illness‐death” model when all transition times are interval censored H Frydman, T Gerds, R Grøn, N Keiding Biometrical Journal 55 (6), 823-843, 2013 | 13 | 2013 |
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy E Miller, A Doshi, R Grøn, E Jódar, P Őrsy, MF Ranthe, D Sugimoto, ... Diabetes, Obesity and Metabolism 21 (12), 2643-2650, 2019 | 10 | 2019 |
Misspecified poisson regression models for large‐scale registry data: inference for ‘large n and small p’ R Grøn, TA Gerds, PK Andersen Statistics in medicine 35 (7), 1117-1129, 2016 | 10 | 2016 |
Binomial regression models R Grøn, TA Gerds Handbook of Survival Analysis, 221, 2013 | 10 | 2013 |
The benefit of insulin degludec/liraglutide (IDegLira) compared with basal-bolus insulin therapy is consistent across participant subgroups with type 2 diabetes in the DUAL VII … LK Billings, BFR Agner, Y Altuntas, R Grøn, N Halladin, DC Klonoff, ... Journal of diabetes science and technology 15 (3), 636-645, 2021 | 9 | 2021 |
Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal-bolus (BB) therapy in patients with type 2 diabetes (T2D): DUAL VII trial LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ... Diabetes 66, A36-A36, 2017 | 4 | 2017 |
Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics LK Billings, Y Altuntas, DC Klonoff, N Tentolouris, R Grøn, N Halladin, ... Canadian Journal of Diabetes 42 (5), S47, 2018 | 3 | 2018 |
IDegLira improves glycaemic control in subjects with type 2 diabetes uncontrolled on basal insulin without deterioration despite discontinuing pre-trial sulphonylurea A Janez, R Silver, T Vilsboll, R Gron, N Halladin, P Orsy, S Harris Diabetologia 61 (1), S413-S414, 2018 | 2 | 2018 |
Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ... Diabetologia 60, S366-S366, 2017 | 2 | 2017 |
DUAL VIII: longer time to intensification with insulin degludec/liraglutide (IDegLira) vs insulin glargine in a 104-week randomised trial mirroring clinical practice VR Aroda, G Gonzalez-Galvez, M Haluzik, RJ Silver, R Gron, N Halladin, ... DIABETOLOGIA 62, S95-S96, 2019 | 1 | 2019 |
148-OR: IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy H Watada, BF Agner, A Doshi, R GRØN, MF Ranthe, LK Billings Diabetes 68 (Supplement_1), 2019 | 1 | 2019 |
Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis K Brown-Frandsen, SS Emerson, SP Marso, DK Mcguire, TR Pieber, ... Diabetes 67 (Supplement_1), 2018 | 1 | 2018 |